Table 2.

Use of AD medication and patients with fractures during follow-up

Characteristic	Diabetic patients (%)	Controls (%)
	(n = 180,049)	(n = 490,147)
Use of AD medication any time during follow-up
Biguanide	122,751 (68.2)	–
sulfonyluerum	137,326 (76.3)	–
TZD	7,603 (4.2)	–
Insulin	42,525 (23.6)	–
Other	17,865 (9.9)	–
Any fracture	22,978 (12.8)	66,401 (13.5)
Foot/ankle	3,180 (1.8)	8,003 (1.6)
Tibia/fibula	2,274 (1.3)	5,552 (1.1)
Hand/wrist	2,694 (1.5)	8,187 (1.7)
Osteoporotic	14,910 (8.3)	44,031 (9.0)
Hip	5,642 (3.1)	15,166 (3.1)
Vertebral	1,221 (0.7)	3,341 (0.7)
Radius/ulna	3,884 (2.2)	15,138 (3.1)
Humerus	2,926 (1.6)	7,121 (1.5)
Ribs	772 (0.4)	2,087 (0.4)

TZD thiazolidinedione, AD antidiabetic